Overcoming resistance in chronic myelogenous leukemia
S Cooper, FJ Giles, MR Savona - Leukemia & lymphoma, 2009 - Taylor & Francis
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
Overcoming resistance in chronic myelogenous leukemia.
S Cooper, FJ Giles, MR Savona - Leukemia & Lymphoma, 2009 - europepmc.org
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
Overcoming resistance in chronic myelogenous leukemia.
S Cooper, FJ Giles, MR Savona - Leukemia & Lymphoma, 2009 - search.ebscohost.com
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
Overcoming resistance in chronic myelogenous leukemia
S Cooper, FJ Giles, MR Savona - Leukemia and …, 2009 - scholars.northwestern.edu
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
Overcoming resistance in chronic myelogenous leukemia
S Cooper, FJ Giles, MR Savona - Leukemia & lymphoma, 2009 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …